INTRODUCTION
Postoperative ileus is an inevitable event after major abdominal surgery. It is caused by the cessation of the migrating motor complex (MMC), by hyperactivity of the sympathetic nervous system, by local inflammation secondary to surgery, and by the inhibitory effect of endogenous or exogenous opioids on gastrointestinal motility.
Clinically, it is characterized by bowel distention, lack of bowel sounds, accumulation of gastrointestinal gas and fluid, and delayed passage of flatus and stool. Postoperative ileus can lead to cramp abdominal pain, nausea, vomiting, and potential complications including aspiration and acute gastric distention. When it is prolonged, postoperative ileus can lead to increased morbidity due to nutritional imbalance, length of hospital stay, and healthcare cost. For these reasons, in particular, several pharmacological managements have been proposed [1] .
Erythromycin (EM) is a well-known prokinetic agent. In patients with diabetic gastroparesis, EM, which stimulates thesurgery.or.kr the gastric antral and duodenal motilin receptor, significantly improves delayed gastric emptying of both solids and liquids [2] . It has also been shown to have potential benefits in patients with postvagotomy gastroparesis [3] .
Although studies on the effects of EM in postoperative ileus are progressing these days, there have been only a few well designed clinical trials that have examined the use of EM in the postoperative setting [4] [5] [6] [7] [8] [9] .
The aim of this study was to determine the effect of EM for the improvement of gastrointestinal motility in subtotal gastrectomized patients. We used radio-opaque Kolomarks as the objective method. Therefore, we hypothesized that Kolomarks would pass through the gastrointestinal tract more rapidly in the EM group than in the control group.
METHODS

Data collection
The study was designed and implemented as a prospective, controlled clinical trial. From March 2007 to February 2008, all patients who were scheduled for subtotal gastrectomy due to gastric cancer at our institution were included in the study. The institutional review board approved this study, and each participant provided informed, written consent.
The patients were selected to one of two groups, either the control or EM group. Starting from the day of the operation to the 2nd postoperative day, patients in the EM group received intravenously 200 mg of EM infusion for 30 minutes in 100 mL of normal saline at 7:00 PM. In the control group, the patients were treated with conventional management without prokinetic agents. All patients during the observation period had their perioperative medications related to gastrointestinal motility stopped except for EM in the EM group.
Surgical methods
All patients had stomach cancer. We classified the cancer staging using the American Joint Committee on Cancer, 8th edition. Subtotal gastrectomy with gastroduodenostomy (Billroth I) or gastrojejunostomy (Billroth Preoperative bowel preparation used one bottle of oral sodium biphosphate and one-half polyethylene glycol.
Postoperative pain medications included patient-controlled analgesia with opioids and local analgesia administered by the anesthesiologist.
Data analysis
All patients in both groups had abdominal X-ray films taken on the 1st, 3rd, 5th, and 7th postoperative day. We counted the number of Kolomarks on each day. In addition, all patients had their passage of flatus checked daily by patient interview. We allowed all patients to have a meal after passage of flatus starting from sips of water to a soft diet in an incrementally manner each day. The length of the hospital stay was from the day of the operation to the discharge day since the patients' hospital stay for the preoperative evaluation varied. Glucose levels were measured on the 1st, 3rd, and 7th postoperative day in order to identify the correlation to bowel motility. We decided to discharge the patients, when the patients had a tolerable soft diet.
No adverse side effects potentially caused by EM were found in patients, which included nausea, emesis, abdominal pain, allergic reaction, and arrhythmia.
Statistical analysis
Comparisons between patients with and without EM Values are presented as mean ± SD (range) or number (%). EM, erythromycin; PCA, patients-controlled analgesia. 
RESULTS
Demographics of the patients
Twenty-eight patients were enrolled in the study. Three patients with diabetes were excluded because we identified that the stimulation of antral motility by EM was attenuated by hyperglycemia [10] . In addition, another patient with esophageal cancer was ruled out due to a delayed hospital stay. The data from the 24 patients were used for the calculations in this study. However, no significant differences were found for the demographics between the two groups ( Table 1) .
Clinical outcomes
The mean values for the glucose levels on the 1st, 3rd, and 7th postoperative day were higher in the EM group than in the control group, although there were no sig- day, also, were higher in the EM group than in the control group (0.4 ± 0.7 in the control group vs. 1.2 ± 1.6 in the EM group, 5.2 ± 12.4 in the control group vs. 10.5 ± 17.7 in the EM group, 19.9 ± 22.6 in the control group vs. 23.6 ± 25.1 in the EM group, respectively). However, we only found a significant difference for the number of Kolomarks passed by the stomach on the 3rd postoperative day (P = 0.026) ( Table 2) .
DISCUSSION
Motilin is a 22-amino acid that is secreted by the enterochromaffin cells of the duodenum and proximal small intestine. This hormone binds to high affinity motilin receptors that have been found in the stomach, the duodenum, and the colon [11] . Motilin receptor stimulation initiates the interdigestive (phase III) MMC. Return of an effective MMC is one of the important components for the resolution of postoperative ileus.
EM, discovered in 1952, was the first macrolide to be introduced into clinical practice [12] . It has been known for over 25 years that it acts as a motilin receptor agonist in the gut and gallbladder [13] . The intravenous form is the most potent stimulant of solid and liquid gastric emptying [14, 15] . EM binds to motilin receptors and hence, increases the amplitude of antral peristalsis, triggers premature MMC phase III activity, and stimulates gastric emptying [16] .
Different doses of EM may have different effects [2] . dense in the stomach and decrease in density as they progress distally through the GI tract. Evidence suggests that motilin receptors are present in the colon but to a considerably lesser degree than in the remainder of the GI tract [11, [17] [18] [19] . Consequently, the effect of EM on colonic motility and on the treatment of lower GI abnormalities has been inconsistent [20] .
Interestingly, EM has also been shown to accelerate emptying in post-vagotomy and antrectomy patients [21] .
This may be due to its stimulatory effects on the fundus.
Vagus nerve activity appears to be more important in the stomach, where it promotes receptive relaxation of the fundus and contraction of the antrum, facilitating gastric emptying [22] . After vagotomy, emptying of liquids may be normal or accelerated, but emptying of solids is impaired. This can occur after peptic ulcer surgery but is more likely after gastric resection for malignancy or after inadvertent vagal nerve injury during antireflux surgery.
In patients who underwent antrectomy and vagotomy, EM was shown to accelerate gastric emptying by roughly 40% as measured by solid-phase gastric emptying scintigraphy [15, 21] . In a randomized controlled trial in 118 patients who underwent pancreaticoduodenectomy, intravenous EM reduced gastroparesis by 37% (measured by solid-phase gastric emptying study) and also reduced the need for nasogastric tube reinsertion [6] .
In our study, we expected that the migration velocity of the Kolomarks passed by the stomach would accelerate in the EM group, although the patients had received a truncal vagotomy. As a result, we found that Kolomarks in the EM group were passed by the stomach more rapidly than in the control group on the 3rd postoperative day. There have been several studies on EM use postoperatively [4] [5] [6] 8, 9, 23] . However, the studies did not prove exactly the effects of EM in the gastrointestinal tract postoperatively.
Most of those studies used clinical parameters in order to obtain endpoints. Our study was more accurate than the other studies since the results of our study were calculated by an objective method (Kolomarks). However, our study also had limitations. Although we were able to distinguish between stomach gas and transverse colon gas, Kolomarks located in the transverse colon were confusing. In 
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